Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Central Wisconsin Cancer Program at Agnesian HealthCare
mi
from
Fond du Lac, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated:  11/23/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Pregabalin in Treating Women With Hot Flashes
A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes
Status: Enrolling
Updated: 11/23/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
Vaccination Of High Risk Breast Cancer Patients With Heptavalent Antigen - Keyhole Limpet Hemocyanin Conjugate Plus The Immunological Adjuvant QS21
Status: Enrolling
Updated:  11/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
Vaccination Of High Risk Breast Cancer Patients With Heptavalent Antigen - Keyhole Limpet Hemocyanin Conjugate Plus The Immunological Adjuvant QS21
Status: Enrolling
Updated: 11/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Wilshire Oncology Medical Group La Verne
mi
from
*see Various Departments*, CA
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Wilshire Oncology Medical Group La Verne
mi
from
*see Various Departments*, CA
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Compassionate Cancer Care Medical Group Dept.ofCCCMG
mi
from
Fountain Valley, CA
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Compassionate Cancer Care Medical Group Dept.ofCCCMG
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Loma Linda University Dept.ofLomaLindaCancerCent(3)
mi
from
Loma Linda, CA
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Loma Linda University Dept.ofLomaLindaCancerCent(3)
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
University of California at Los Angeles Dept.of UCLA Dept.ofMed.
mi
from
Los Angeles, CA
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
University of California at Los Angeles Dept.of UCLA Dept.ofMed.
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)
mi
from
Atlanta, GA
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
North Shore University Health System
mi
from
Evanston, IL
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
North Shore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Peninsula Regional Medical Center Deptof Oncology and Hematology
mi
from
Salisbury, MD
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Peninsula Regional Medical Center Deptof Oncology and Hematology
mi
from
Salisbury, MD
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CRAD001J2101
mi
from
St. Louis, MO
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Washington University School Of Medicine-Siteman Cancer Ctr StudyCoordinator:CRAD001J2101
mi
from
St. Louis, MO
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Cancer Centers of the Carolinas CC of C -Eastside
mi
from
Greenville, SC
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Cancer Centers of the Carolinas CC of C -Eastside
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Sammons Cancer Center - Texas Oncology
mi
from
Dallas, TX
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Sammons Cancer Center - Texas Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated:  11/24/2015
Novartis Investigative Site
mi
from
Charleroi,
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer
Status: Enrolling
Updated: 11/24/2015
Novartis Investigative Site
mi
from
Charleroi,
Click here to add this to my saved trials
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated:  11/25/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated: 11/25/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated:  11/25/2015
Massachusetts General Hospital
mi
from
Boston, MA
Ruxolitinib in Patients With Breast Cancer
Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Status: Enrolling
Updated: 11/25/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals With Patients Diagnosed With Advanced Breast Cancer
Status: Enrolling
Updated:  11/25/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals With Patients Diagnosed With Advanced Breast Cancer
Status: Enrolling
Updated: 11/25/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
Pilot Trial of Aerobic and Resistance Exercise Training for the Primary Prevention of Musculoskeletal Side Effects From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
Status: Enrolling
Updated:  11/25/2015
Baltimore VA Medical Center
mi
from
Baltimore, MD
Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
Pilot Trial of Aerobic and Resistance Exercise Training for the Primary Prevention of Musculoskeletal Side Effects From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
Status: Enrolling
Updated: 11/25/2015
Baltimore VA Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Ironwood Cancer and Research Centers
mi
from
Chandler, AZ
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Ironwood Cancer and Research Centers
mi
from
Chandler, AZ
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Highlands Oncology Group DeptofHighlandsOncologyGrp(2)
mi
from
Fayetteville, AR
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Highlands Oncology Group DeptofHighlandsOncologyGrp(2)
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C
mi
from
Anaheim, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C
mi
from
Anaheim, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Comprehensive Blood and Cancer Center Dept. of CBCC (3)
mi
from
Bakersfield, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Comprehensive Blood and Cancer Center Dept. of CBCC (3)
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Cancer Care Associates Dept.ofCancerCareAssoc. (2)
mi
from
Fresno, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Cancer Care Associates Dept.ofCancerCareAssoc. (2)
mi
from
Fresno, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Grass Valley Hematology Oncology Medical Group Dept. of Grass Valley Hem/Onc
mi
from
Grass Valley, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Grass Valley Hematology Oncology Medical Group Dept. of Grass Valley Hem/Onc
mi
from
Grass Valley, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Scripps Clinic SC
mi
from
La Jolla, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Scripps Clinic SC
mi
from
La Jolla, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3
mi
from
Los Angeles, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Sharp Memorial Hospital SharpClinicalOncologyResearch
mi
from
San Diego, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Sharp Memorial Hospital SharpClinicalOncologyResearch
mi
from
San Diego, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
University of California San Francisco (UCSF) Medical Center
mi
from
San Francisco, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
University of California San Francisco (UCSF) Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ
mi
from
Santa Monica, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
St Joseph Heritage Healthcare Dept. of RRMG (4)
mi
from
Santa Rosa, CA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
St Joseph Heritage Healthcare Dept. of RRMG (4)
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Comprehensive Cancer Center - Boca Raton Deerfield Beach
mi
from
Boca Raton, FL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Comprehensive Cancer Center - Boca Raton Deerfield Beach
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Florida Cancer Research Institute
mi
from
Davie, FL
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Florida Cancer Specialists DeptofFloridaCancerSpecialists
mi
from
Fort Myers, FL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Florida Cancer Specialists DeptofFloridaCancerSpecialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Memorial Hospital Memorial Cancer Institute
mi
from
Hollywood, FL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Memorial Hospital Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)
mi
from
Orlando, FL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)
mi
from
Orlando, FL
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Palm Beach Cancer Institute, LLC
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Florida Medical Clinic PA Dept.ofFloridaMedicalClinic
mi
from
Zephyrhills, FL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Florida Medical Clinic PA Dept.ofFloridaMedicalClinic
mi
from
Zephyrhills, FL
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Georgia Cancer Specialists. Drug Ship
mi
from
Decatur, GA
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Georgia Cancer Specialists. Drug Ship
mi
from
Decatur, GA
Click here to add this to my saved trials
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated:  11/25/2015
Rush University Medical Center Study Coordinator
mi
from
Chicago, IL
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status: Enrolling
Updated: 11/25/2015
Rush University Medical Center Study Coordinator
mi
from
Chicago, IL
Click here to add this to my saved trials